Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication

被引:455
作者
Pisella, PJ
Pouliquen, P
Baudouin, C
机构
[1] Univ Paris 05, Dept Ophthalmol, APHP Ambroise Pare Hosp, F-92100 Boulogne, France
[2] CHU Bretonneau, Dept Ophthalmol, F-37044 Tours 1, France
[3] Thea Labs, F-63017 Clermont Ferrand 2, France
[4] Univ Paris 05, Natl Hosp 15 20, F-75012 Paris, France
关键词
D O I
10.1136/bjo.86.4.418
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim: To determine the incidence of ocular toxicity of preservatives with glaucoma medications. Methods: A prospective epidemiological survey was carried out in 1999 by 249 ophthalmologists on A 107 patients. Ocular symptoms, conjunctiva, cornea, and eyelids were assessed. A chi(2) test was used for differences between preserved eye drops (P) and preservative free eye drops (PIP). Results: 84% patients used P, 13% received PF, and 3% a combination of P and PF eye drops. All symptoms were more prevalent with P than with PF drops (p<0.001): discomfort upon instillation (43% versus 17%), and symptoms between instillations such as burning-stinging (40% versus 22%), foreign body sensation (31% versus 14%), dry eye sensation (23% versus 14%), tearing (21% versus 14%), and eyelid itching (18% versus 10%). An increased incidence (>2 times) of ocular signs was seen with P eye drops. The prevalence of signs and symptoms was dose dependent, increasing with the number of P drops. A reduction in the symptoms and signs was observed when patients changed from P to PF eye drops (p<0.001). Conclusions: Symptoms and signs are less prevalent when PF drops are used. Moreover, most of the adverse reactions induced by P glaucoma medication are reversible after removing preservatives.
引用
收藏
页码:418 / 423
页数:6
相关论文
共 53 条
[1]  
Ariturk N, 1997, INT OPHTHALMOL, V20, P57
[2]  
Baudouin C, 1996, Curr Opin Ophthalmol, V7, P80, DOI 10.1097/00055735-199604000-00014
[3]   Ocular surface inflammatory changes induced by topical antiglaucoma drugs -: Human and animal studies [J].
Baudouin, C ;
Pisella, PJ ;
Fillacier, K ;
Goldschild, M ;
Becquet, F ;
De Saint Jean, M ;
Béchetoille, A .
OPHTHALMOLOGY, 1999, 106 (03) :556-563
[4]  
BAUDOUIN C, 1994, OPHTHALMOLOGY, V101, P454
[5]   Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers [J].
Baudouin, C ;
de Lunardo, C .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1998, 82 (01) :39-42
[6]   Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface [J].
Becquet, F ;
Goldschild, M ;
Moldovan, MS ;
Ettaiche, M ;
Gastaud, P ;
Baudouin, C .
CURRENT EYE RESEARCH, 1998, 17 (04) :419-425
[7]   CHRONIC PROGRESSIVE CONJUNCTIVAL CICATRIZATION [J].
BERNAUER, W ;
BROADWAY, DC ;
WRIGHT, P .
EYE, 1993, 7 :371-378
[8]  
Bohn RL, 2000, J GLAUCOMA, V9, P38
[9]  
BOUR T, 1993, J FR OPHTALMOL, V16, P367
[10]  
Bourcier T, 2000, INVEST OPHTH VIS SCI, V41, P120